背景:标准的快速医疗保健互操作性资源(FHIR)广泛用于健康信息技术。然而,它作为健康研究的标准仍然不那么普遍。为了更有效地使用现有数据源进行健康研究,数据互操作性变得越来越重要。FHIR通过提供“公共卫生与研究”和“循证医学”等资源领域来提供解决方案,同时使用已经建立的网络技术。因此,FHIR可以帮助标准化不同数据源的数据,并提高健康研究的互操作性。
目的:我们研究的目的是对现有文献进行系统回顾,并确定FHIR在健康研究中的实施现状和未来可能的方向。
方法:我们搜索了PubMed/MEDLINE,Embase,WebofScience,IEEEXplore,和Cochrane图书馆数据库,用于2011年至2022年发表的研究。包括调查FHIR在健康研究中使用的研究。2011年之前发表的文章,摘要,reviews,社论,专家意见被排除在外。我们遵循PRISMA(系统审查和荟萃分析的首选报告项目)指南,并在PROSPERO(CRD42021235393)注册了这项研究。在表格和附图中进行数据合成。
结果:我们确定了总共998项研究,其中49项研究符合纳入条件.在49项研究中,大多数(73%,n=36)涵盖了临床研究领域,而其余的研究集中在公共卫生或流行病学(6%,n=3)或未指定他们的研究领域(20%,n=10)。研究使用FHIR进行数据采集(29%,n=14),数据标准化(41%,n=20),分析(12%,n=6),招聘(14%,n=7),和同意管理(4%,n=2)。大多数(55%,27/49)的研究采用了通用方法,55%(12/22)的研究侧重于特定的医学专业(传染病,基因组学,肿瘤学,环境卫生,成像,和肺动脉高压)报告了它们的解决方案可用于其他用例。大多数(63%,31/49)的研究报告使用其他数据模型或术语:医学临床术语的系统化命名法(29%,n=14),逻辑观察标识符名称和代码(37%,n=18),国际疾病分类第10次修订(18%,n=9),观察性医疗结果伙伴关系通用数据模型(12%,n=6),和其他(43%,n=21)。只有4项(8%)研究使用了“公共卫生与研究”领域的FHIR资源。\"使用FHIR的限制包括FHIR资源内容的可能变化,安全,法律事务,以及对FHIR服务器的需求。
结论:我们的审查发现,FHIR可以在健康研究中实施,在大多数用例中,应用领域是广泛和可推广的。国际术语的实施很普遍,和其他标准,如观察医疗结果伙伴关系通用数据模型可以用作FHIR的补充。限制,如FHIR内容的变化,缺乏FHIR的实施,安全,和法律事务需要在未来的版本中解决,以扩大FHIR的使用,因此,健康研究中的互操作性。
BACKGROUND: The standard Fast Healthcare Interoperability Resources (FHIR) is widely used in health information technology. However, its use as a standard for health research is still less prevalent. To use existing data sources more efficiently for health research, data interoperability becomes increasingly important. FHIR provides solutions by offering resource domains such as \"Public Health & Research\" and \"Evidence-Based Medicine\" while using already established web technologies. Therefore, FHIR could help standardize data across different data sources and improve interoperability in health research.
OBJECTIVE: The aim of our study was to provide a systematic
review of existing literature and determine the current state of FHIR implementations in health research and possible future directions.
METHODS: We searched the PubMed/MEDLINE, Embase, Web of Science, IEEE Xplore, and Cochrane Library databases for studies published from 2011 to 2022. Studies investigating the use of FHIR in health research were included. Articles published before 2011, abstracts, reviews, editorials, and expert opinions were excluded. We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and registered this study with PROSPERO (CRD42021235393). Data synthesis was done in tables and figures.
RESULTS: We identified a total of 998 studies, of which 49 studies were eligible for inclusion. Of the 49 studies, most (73%, n=36) covered the domain of clinical research, whereas the remaining studies focused on public health or epidemiology (6%, n=3) or did not specify their research domain (20%, n=10). Studies used FHIR for data capture (29%, n=14), standardization of data (41%, n=20), analysis (12%, n=6), recruitment (14%, n=7), and consent management (4%, n=2). Most (55%, 27/49) of the studies had a generic approach, and 55% (12/22) of the studies focusing on specific medical specialties (infectious disease, genomics, oncology, environmental health, imaging, and pulmonary hypertension) reported their solutions to be conferrable to other use cases. Most (63%, 31/49) of the studies reported using additional data models or terminologies: Systematized Nomenclature of Medicine Clinical Terms (29%, n=14), Logical Observation Identifiers Names and Codes (37%, n=18), International Classification of Diseases 10th Revision (18%, n=9), Observational Medical Outcomes Partnership common data model (12%, n=6), and others (43%, n=21). Only 4 (8%) studies used a FHIR resource from the domain \"Public Health & Research.\" Limitations using
FHIR included the possible change in the content of
FHIR resources, safety, legal matters, and the need for a
FHIR server.
CONCLUSIONS: Our
review found that
FHIR can be implemented in health research, and the areas of application are broad and generalizable in most use cases. The implementation of international terminologies was common, and other standards such as the Observational Medical Outcomes Partnership common data model could be used as a complement to FHIR. Limitations such as the change of
FHIR content, lack of
FHIR implementation, safety, and legal matters need to be addressed in future releases to expand the use of FHIR and, therefore, interoperability in health research.